Published On: 8/2/2017
TARGET PharmaSolutions Enrolls First Participant in its Inflammatory Bowel Disease (IBD) Community
CHAPEL HILL, NC – (August 2, 2017) – TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce enrollment of the first participant in its Inflammatory Bowel Disease community, TARGET-IBD, which includes adult and pediatric patients with ulcerative colitis, Crohn’s disease and indeterminate colitis.
TARGET-IBD is led by an academic steering committee chaired by Bruce Sands, MD (Mount Sinai), David Rubin, MD (University of Chicago), and Millie Long, MD (University of North Carolina). Dr. Bruce Sands noted that “We are excited to achieve this significant milestone and to advance the critical work of TARGET-IBD. By following both adult and pediatric populations in the real-world setting, this study provides an invaluable opportunity to enhance understanding of the natural disease course of IBD and, ultimately, to evaluate treatment regimens within different patient subsets.”
TARGET-IBD’s first participant enrolled on July 24th, 2017. TARGET-IBD will collect retrospective and prospective data on its enrolled patients and will develop a biorepository which its stakeholders can access for translational studies of viral resistance, genomics, and biomarkers. TARGET-IBD will enroll up to 15,000 patients at up to 100 sites over the next few years.
TARGET PharmaSolutions provides insights and actions to improve clinical, medical, and commercial outcomes throughout the pharmaceutical development and commercialization process. The TARGET model organizes a community of stakeholders, including pharmaceutical manufacturers, key opinion leaders, regulatory agencies, and patient advocacy groups, around a specific disease to generate real world evidence about the natural history of the given disease, current treatment paradigm, and patient outcomes. This model enables TARGET’s stakeholders to answer critical strategic and planning questions and to fulfill regulatory and payer requests. The TARGET model also provides its stakeholders access to a biorepository linked to validated clinical outcomes, including patient reported outcomes (PROs).
TARGET PharmaSolutions was formed in February, 2015 and has four disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), and TARGET-IBD (inflammatory bowel disease). The TARGET model is based on the success of HCV-TARGET, a case study in Hepatitis C. Formed in 2011 by Drs. Michael Fried, MD (University of North Carolina) and David Nelson, MD (University of Florida), HCV-TARGET has enrolled over 11,000 patients and has generated data that has been used by physicians, payers, and regulatory agencies around the world.
About TARGET PharmaSolutions
Headquartered in Durham, NC, TARGET PharmaSolutions is a privately held real-world data solutions company that provides pharmaceutical and biotechnology partners a more efficient way to generate data in the real-world setting. TARGET PharmaSolutions has six disease communities: TARGET-NASH (nonalcoholic steatohepatitis), TARGET-PBC (primary biliary cholangitis), TARGET-HCC (hepatocellular carcinoma), TARGET-IBD (inflammatory bowel disease), TARGET-DERM (immune mediated skin conditions) and TARGET-HBV (hepatitis B).
For more information, visit www.targetpharmasolutions.com.
984.234.0268 ext 205
05/07/2020Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
04/14/2020TARGET-NASH Observational Study Reaches 5,000 Enrolled Patients
03/17/2020TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
03/13/2020TARGET PharmaSolutions Launches Real-World Asthma Study